Patents Assigned to Welfide Corporation
-
Patent number: 6528514Abstract: The present invention relates to an IgE antibody production inhibitor and an autoimmune disease suppressant containing a heterocyclic amide compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient wherein R represents a hydrogen atom, alkyl, —CHO, —COOH, etc.; R5, R6 and R7 represent each hydrogen, alkyl, aryl, etc.; M represents a carbon atom or a nitrogen atom; Y represents aryl, etc.; and Z represents hydrogen, alkyl, aryl, etc.Type: GrantFiled: December 20, 2000Date of Patent: March 4, 2003Assignee: Welfide CorporationInventors: Fujio Kobayashi, Shigeki Kuwahara, Naruyasu Komorita, Koji Naito, Teruaki Imada, Tsutomu Yoshikawa
-
Patent number: 6485725Abstract: A method for producing an immunoglobulin preparation for intravenous injection, which comprises the steps of: fractionating an immunoglobulin-containing solution with 4 to 10 w/v% of polyethylene glycol having a molecular weight of from 1,000 to 10,000, at a pH value of from 4.5 to 6.5, an ionic strength of from 0.0001 to 0.1 M and a temperature of from 0 to 4° C. to recover a supernatant fraction; and concentrating the supernatant fraction at a pH of from 3.5 to 5.0.Type: GrantFiled: May 3, 2000Date of Patent: November 26, 2002Assignee: Welfide CorporationInventors: Yutaka Hirao, Motonori Hashimoto, Tae Kitamura, Yahiro Uemura
-
Publication number: 20020127228Abstract: A method for screening an apoptosis inhibitor characterized by screening a candidate via an effect on PGT. A cell protecting agent containing as the active ingredient a substance which can be incorporated into cells via prostaglandin transporter (PGT); and a screening method therefor comprising measuring the uptake into cells via PGT. An apoptosis inducer containing as the active ingredient a substance having a PGT inhibitory effect; and a screening method therefor comprising measuring the ability to induce apoptosis of cells with the expression of PGT. Because of having a cell apoptosis inhibitory effect, the cell protecting agent is useful as a nerve cell apoptosis inhibitor, a nerve cell protecting agent, etc. and applicable to the prevention or treatment of nervous diseases, etc. The apoptosis inducer is useful in preventing and/or treating diseases in association with cell proliferation such as tumor, etc.Type: ApplicationFiled: June 4, 2001Publication date: September 12, 2002Applicant: WELFIDE CORPORATIONInventors: Tooru Kawamura, Satoshi Horie, Toshiaki Akira, Norifumi Nakamura, Tomoyuki Maruyama, Kazutaka Hayashi
-
Publication number: 20020062491Abstract: A method for producing primary hepatocellular carcinoma-bearing model animals is provided and is made easily and surely in a large scale. The model animals are effectively utilized for a method of diagnosis and therapy of primary hepatocellular carcinoma.Type: ApplicationFiled: September 19, 2001Publication date: May 23, 2002Applicant: WELFIDE CORPORATIONInventor: Shun-Ichiro Ishii
-
Patent number: 6329410Abstract: An aqueous liquid preparation, which has a pH of from 3 to 5 and comprises (R)-(−)-3-methyl-3-methyl -sulfonyl-1-(1H-1,2,4-triazol-1-yl)-2-[4-(trifluoromethyl)phenyl]butan-2-ol or a pharmaceutically acceptable salt thereof; and an injection for intravenous administration comprising the aqueous liquid preparation.Type: GrantFiled: June 23, 2000Date of Patent: December 11, 2001Assignees: Welfide Corporation, SPP Co., Ltd.Inventors: Tsuneo Fujii, Toshihiro Baba
-
Patent number: 6303144Abstract: A controlled release preparation containing at least one kind of a pharmaceutically active ingredient, a male piece and a female piece, the pieces fitting together to enclose the active substance therein, wherein the male piece is made from a material that gels in the intestinal juice, is disclosed. In a preferable mode, the male piece contains an ethyl acrylate-methyl methacrylate-trimethylammonioethyl methacrylate chloride copolymer and a methacrylic acid-ethyl acrylate copolymer. In a preferable mode, the female piece is made from a water insoluble polymer. In a preferable mode, the dosage form is a tablet or a capsule.Type: GrantFiled: August 10, 2000Date of Patent: October 16, 2001Assignee: Welfide CorporationInventor: Tomoyuki Omura
-
Patent number: 6288061Abstract: The present invention relates to the imidazole derivative of the following formula (I) wherein R1 is hydrogen, optionally substituted alkyl and the like, R2 is hydrogen, optionally substituted alkyl and the like, R3is optionally substituted heteroaryl, R4 is optionally substituted cycloalkyl, optionally substituted phenyl and the like, provided that when R1 is hydrogen, and R2 and R4 are the same or different and each is phenyl or phenyl substituted by halogen atom, lower alkyl or lower alkoxy, R3 is benzothiazolyl or thiazolyl substituted by phenyl, the imidazole derivative of the following formula (XII) wherein R6 is optionally substituted phenyl or optionally substituted heteroaryl and R7 is substituted phenyl, and pharmaceutically acceptable salts thereof.Type: GrantFiled: June 21, 2000Date of Patent: September 11, 2001Assignee: Welfide CorporationInventors: Hiroyuki Sueoka, Jouji Yasuoka, Akira Nishiyama, Masatoshi Kiuchi, Katsuya Yamamoto, Kunio Sugahara, Syuji Ehara, Kei Sakata
-
Patent number: 6288113Abstract: An angiogenesis promoter containing a compound of the following formula (I) wherein R1 is acyl, R2 is alkyl, R3 and R4 are the same or different and each is hydrogen atom or hydroxy protecting group and R5 is alkyl, as an active ingredient. This compound itself not only has an angiogenesis promoting effect but also potentiates the angiogenic effect by a drug (e.g., b-FGF) having such effect. Therefore, it can express the angiogenesis promoting effect more effectively in the ischemic tissues and the site under different disease state, where b-FGF has locally increased.Type: GrantFiled: June 21, 2000Date of Patent: September 11, 2001Assignees: Welfide Corporation, Seikagaku CorporationInventors: Yasuhiro Egi, Yoshiji Kubo, Satoru Inoue, Hideaki Kido, Masakuni Nishikawa, Kazutaka Hayashi
-
Patent number: 6284915Abstract: A process for preparing 2-amino malonic acid derivatives of formula (1): wherein A is linear or branched chain alkylene having from 1 to 10 carbon atoms, R1 is linear or branched chain alkyl having from 2 to 20 carbon atoms, R2 and R3 are the same or different, and are lower alkyl or aralkyl, and R4 is a protecting group, which process comprises the steps of reducing a compound of formula (6): wherein A is linear or branched chain alkylene having from 1 to 10 carbon atoms, R1 is linear or branched chain alkyl having from 2 to 20 carbon atoms, R2 and R3 are the same or different, and are lower alkyl or aralkyl, and R4 is a protecting group.Type: GrantFiled: March 3, 1999Date of Patent: September 4, 2001Assignees: Taito Co., LTD, Welfide CorporationInventors: Susumu Hirase, Shigeo Sasaki, Masahiko Yoneta, Ryoji Hirose, Tetsuro Fujita
-
Patent number: 6284758Abstract: An angiogenesis promoter and angiogenesis potentiator containing a pyridazinone compound of the formula (I) wherein each symbol is as defined in the specification, or a pharmacologically acceptable salt thereof, as an active ingredient. The pyridazinone compound (I) and a pharmacologically acceptable salt thereof in the present invention promote angiogenesis and potentiate the angiogenic effect of a drug having such effect, and are useful as an angiogenesis promoter and angiogenesis potentiator.Type: GrantFiled: February 25, 2000Date of Patent: September 4, 2001Assignees: Welfide Corporation, Nissan Chemical Industries, Ltd.Inventors: Yasuhiro Egi, Hideaki Kido, Kazutaka Hayashi, Yoshiji Kubo, Norifumi Nakamura
-
Patent number: 6277888Abstract: The present invention provides a pharmaceutical composition containing 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol or a pharmaceutically acceptable acid addition salt thereof and a lecithin, and containing a saccharide if desired, which can be formulated into a liquid preparation, and which is suitable for the suppression of rejection in organ or bone marrow transplantation, for an immunosuppressive sustention therapy or for the treatment of autoimmune diseases.Type: GrantFiled: January 6, 2000Date of Patent: August 21, 2001Assignee: Welfide CorporationInventors: Atsushi Sakai, Rumiko Masuda
-
Patent number: 6271225Abstract: A condensed thiophene compound of the formula (I) wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof and hydrates thereof. The compound of the formula (I) of the present invention is useful as a novel antipsychotic agent which is effective for both positive symptoms and negative symptoms of schizophrenia, which is associated with less side effects such as extrapyramidal motor disorder and the like and which is less associated with serious side effects such as agranulocytosis and the like. In addition, this compound is also useful as a therapeutic agent of Alzheimer's disease and manic-depressive illness.Type: GrantFiled: July 8, 1999Date of Patent: August 7, 2001Assignee: Welfide CorporationInventors: Koji Seio, Hiroshi Tanaka, Toshiyuki Kohara, Kenji Hashimoto, Masatake Fujimura, Hideki Horiuchi, Hiroshi Yasumatsu, Koreichi Kimura
-
Patent number: 6258834Abstract: The present invention relates to an agent for the prophylaxis and treatment of diabetic complications comprising, as an active ingredient, 4-[&agr;-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid, an optically active compound thereof or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for the prophylaxis and treatment of diabetic complications comprising administering an effective amount of this compound. The medicament of the present invention is useful for the prophylaxis and treatment of diabetic complications, namely, diabetic neuropathy, nephropathy, ophthalmopathy, arteriosclerosis and the like. The action of the drug is long-lasting for very small doses and a single administration a day is sufficient.Type: GrantFiled: February 4, 2000Date of Patent: July 10, 2001Assignee: Welfide CorporationInventors: Yoshiharu Hayashi, Nobuharu Goto
-
Patent number: 6221864Abstract: The present invention relates to an agent for the prophylaxis and treatment of diseases caused by Helicobacter infections, which comprises (S)-1-cyclopropyl-1,4-dihydro-7-[2-(N,N-dimethylaminomethyl)morpholino]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof. The prophylactic and therapeutic agent of the present invention is effective even when used alone in a small dose for a short time, is almost free of problematic side effects such as tolerance and diarrhea, and is low toxic and capable of safe and ensured bacterial eradication. It is useful for the prophylaxis and treatment of diseases caused by Helicobacter infections, particularly, gastritis, gastric ulcer, duodenal ulcer, malignant lymphoma and gastric cancer.Type: GrantFiled: December 23, 1999Date of Patent: April 24, 2001Assignee: Welfide CorporationInventors: Fumihiro Hirayama, Mitsuharu Sano, Nobuhiro Sakurai, Yoshito Yokoyama
-
2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
Patent number: 6214873Abstract: The present invention relates to a compound of the general formula wherein R1, R2, R3 and R4 are each a hydrogen or an acyl, a pharmaceutically acceptable acid addition salt thereof or a hydrate thereof; a pharmaceutical comprising this compound; a pharmaceutical composition comprising this compound and a pharmaceutically acceptable carrier; and 2-amino-2-(2-(4-(1-hydroxy-5-phenylpentyl)phenyl)ethyl)propane-1,3-diol or 2-amino-2-(2-(4-formylphenyl)ethyl)propane-1,3-diol, the derivatives of the two compounds whose amino group and/or hydroxy group are(is) protected or a salt thereof. The compound of the present invention shows superior immunosuppressive action with less toxicity and higher safety, and is useful as a drug for prevention or suppression of rejection of organs or bone marrow transplantation, or as a drug for prevention or treatment of various autoimmune diseases or allergic diseases.Type: GrantFiled: January 5, 2000Date of Patent: April 10, 2001Assignee: Welfide CorporationInventors: Kunitomo Adachi, Yoshiyuki Aoki, Tokushi Hanano, Koji Teshima, Yukio Hoshino, Tetsuro Fujita -
Patent number: 6197829Abstract: An external preparation for topical administration which aims at inhibiting rejection reactions at organ or bone marrow transplantation or treating autoimmune diseases or allergic diseases and contains as the active ingredient 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or a pharmaceutically acceptable acid addition salt thereof.Type: GrantFiled: June 12, 2000Date of Patent: March 6, 2001Assignee: Welfide CorporationInventors: Tsuneo Fujii, Tadashi Mishina, Koji Teshima, Tomonori Imayoshi
-
Patent number: 6187821Abstract: A benzene compound of the formula: wherein each symbol is as defined in the specification; an optically active isomer or salt thereof, a medicinal composition containing the same, and an immunosuppressant containing the same as the active ingredient.Type: GrantFiled: May 12, 1999Date of Patent: February 13, 2001Assignee: Welfide CorporationInventors: Tetsuro Fujita, Kunitomo Adachi, Toshiyuki Kohara, Masatoshi Kiuchi, Kenji Chiba, Koji Teshima, Tadashi Mishina
-
Patent number: 6124437Abstract: An immunoglobulin preparation comprising an immunoglobulin, wherein the preparation contains, as a contaminant, serum albumin in an amount not greater than 10 .mu.g per 50 mg of immunoglobulin; and/or wherein the preparation is free of fine particles which can serve as a nucleus of insoluble foreign matter, and processes for preparing the immunoglobulin preparation are described.Type: GrantFiled: March 18, 1998Date of Patent: September 26, 2000Assignee: Welfide CorporationInventors: Yutaka Hirao, Motonori Hashimoto, Tae Kitamura, Yahiro Uemura
-
Patent number: 6084110Abstract: This invention relates to a stable vitamin C preparation and a method for stabilizing vitamin C preparation. According to the invention, the vitamin C preparation stable for a long period of time can be obtain, since the preparation contains magnesium ions which have the effect of stabilizing vitamin C.Type: GrantFiled: October 28, 1998Date of Patent: July 4, 2000Assignee: Welfide CorporationInventors: Takae Kido, Hideto Kodaira, Koji Munechika, Shunichi Abe, Yasuo Ueda